ICU Medical (NASDAQ:ICUI) updated its FY 2018 earnings guidance on Thursday. The company provided earnings per share guidance of $8.45-8.85 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.60. ICU Medical also updated its FY18 guidance to $8.45-8.85 EPS.
Several research firms have recently weighed in on ICUI. BidaskClub downgraded ICU Medical from a buy rating to a hold rating in a research report on Thursday. TheStreet upgraded ICU Medical from a c+ rating to a b+ rating in a research report on Monday, August 20th. ValuEngine upgraded ICU Medical from a hold rating to a buy rating in a research report on Tuesday, October 2nd. Finally, Zacks Investment Research downgraded ICU Medical from a strong-buy rating to a hold rating in a research report on Thursday, October 11th.
Shares of NASDAQ:ICUI traded down $28.23 on Friday, hitting $232.01. 689,193 shares of the company’s stock were exchanged, compared to its average volume of 175,069. ICU Medical has a 12 month low of $180.45 and a 12 month high of $321.70. The company has a market cap of $5.28 billion, a price-to-earnings ratio of 42.03 and a beta of 0.65.
In related news, VP Thomas D. Mccall sold 11,133 shares of ICU Medical stock in a transaction dated Friday, August 24th. The stock was sold at an average price of $302.56, for a total value of $3,368,400.48. Following the completion of the sale, the vice president now directly owns 3,018 shares in the company, valued at $913,126.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Virginia Ruth Sanzone sold 787 shares of ICU Medical stock in a transaction dated Tuesday, August 28th. The shares were sold at an average price of $303.12, for a total value of $238,555.44. Following the completion of the sale, the vice president now owns 1,367 shares of the company’s stock, valued at $414,365.04. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 711,920 shares of company stock valued at $202,651,956. Corporate insiders own 12.50% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “ICU Medical (ICUI) Updates FY 2018 Earnings Guidance” was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://sportsperspectives.com/2018/11/09/icu-medical-icui-updates-fy-2018-earnings-guidance.html.
ICU Medical Company Profile
ICU Medical, Inc develops, manufactures, and sells medical devices used in vascular therapy, critical care, and oncology applications worldwide. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patient's vein.
Featured Story: How to Invest in Growth Stocks
Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.